General
Preferred name
SB 202190
Synonyms
SB202190 ()
FHPI ()
SB-202190 ()
Oxindole 94 ()
SB 202190 (hydrochloride) ()
SB 202190 hydrochloride ()
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole ()
SB202190 (FHPI) ()
SB 202190 (hydrochloride) ()
P&D ID
PD002796
CAS
152121-30-7
350228-36-3
Tags
available
drug candidate
Drug indication
Pain
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION SB202190 is a potent and selective p38 MAPK inhibitor.
DESCRIPTION SB202190 is a potent and selective p38 MAPK inhibitor, that preferentially inhibits p38α and p38β. (GtoPdb)
DESCRIPTION SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38¦Á and p38¦Â2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits[1][2]. SB202190 induces autophagy[3].
PRICE 29
DESCRIPTION SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38?? and p38??2 (IC50=50/100 nM) selectively and cell-permeably. SB 202190 has antitumor activity and also induces the differentiation of human embryonic stem cells into cardiomyocytes.
DESCRIPTION SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38¦Á and p38¦Â2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 hydrochloride has anti-cancer activity[1][2]. SB202190 hydrochloride induces autophagy[3].
PRICE 75
DESCRIPTION SB 202190 hydrochloride is the salt form of SB 202190.SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38?? and p38??2 with selective, cell-permeable, and antitumor activity, and also induces differentiation of human embryonic stem cells to cardiomyocytes.
DESCRIPTION Phospholipase C inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Highly selective, potent and cell permeable p38 MAP kinase inhibitor. (LOPAC library)
DESCRIPTION Potent, selective inhibitor of p38 MAPK (Tocriscreen Total)
DESCRIPTION Potent, selective inhibitor of p38 MAPK (Tocriscreen Plus)
DESCRIPTION SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38α and p38β2 (IC50=50/100 nM) selectively and cell-permeably. SB 202190 has antitumor activity and also induces the differentiation of human embryonic stem cells into cardiomyocytes. (TargetMol Bioactive Compound Library)
DESCRIPTION SB 202190 is a potent, selective, and cell-permeable inhibitor of p38 MAP kinases, effective against p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively. It inhibits p38 MAP kinases, resulting in blockade of tumor necrosis factor alpha (TNF-alpha) and interleukin-1beta (IL-1beta) production in monocytes. (BOC Sciences Bioactive Compounds)
Cell lines
1
Organisms
2
Compound Sets
21
Axon Medchem Screening Library
1364
BOC Sciences Bioactive Compounds
sb-202190-monohydrochloride-hydrate-cas-350228-36-3-item-188753
Cayman Chemical Bioactives
10010399
21201
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugMAP
DMPFD6Y
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EOS101076
EUbOPEN Chemogenomics Library
EUB0001908
Guide to Pharmacology
4307
JUMP-Target 1 Compound Set
LINCS compound set
10441-101
LOPAC library
MedChem Express Bioactive Compound Library
HY-10295
HY-10295A
Novartis Chemogenetic Library (NIBR MoA Box)
Selleckchem Bioactive Compound Library
SB-202190
TargetMol Bioactive Compound Library
T2301
Tocris Bioactive Compound Library
1264
Tocriscreen Plus
1264
Tocriscreen Total
ZINC Tool Compounds
ZINC000089221712
External IDs
47
Properties
(calculated by RDKit )
Molecular Weight
331.11
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
4
Aromatic Ring Count
4
cLogP
4.65
TPSA
61.8
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.57
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Selectivity
p38 MAPK
MOA
Inhibitor
p38 alpha/beta inhibitor
p38 MAPK inhibitor
Target
p38¦Á
p38¦Â
AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1
MAPK14
Apoptosis related,Autophagy,Ferroptosis,p38 MAPK
Organoid
p38α
p38β
Member status
member
Pathway
Apoptosis
Autophagy
MAPK
MAPK/ERK Pathway
Stem Cell/Wnt
Recommended Cell Concentration
None
Source data